Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 236

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience

Salem, Riad, Gabr, Ahmed, Riaz, Ahsun, Mora, Ronald, Ali, Rehan, Abecassis, Michael, Hickey, Ryan, Kulik, Laura, Ganger, Daniel, Flamm, Steven, Atassi, Rohi, Atassi, Bassel, Sato, Kent, Benson, Al B., Mulcahy, Mary F., Abouchaleh, Nadine, Asadi, Ali Al, Desai, Kush, Thornburg, Bartley, Vouche, Michael, Habib, Ali, Caicedo, Juan, Miller, Frank H., Yaghmai, Vahid, Kallini, Joseph R., Mouli, Samdeep, Lewandowski, Robert J. · 2018 · Hepatology

Abstract

Yttrium‐90 transarterial radioembolization (TARE) is a locoregional therapy (LRT) for hepatocellular carcinoma (HCC). In this study, we present overall survival (OS) outcomes in a 1,000‐patient cohort acquired over a 15‐year period. Between December 1, 2003 and March 31, 2017, 1,000 patients with HCC were treated with TARE as part of a prospective cohort study. A comprehensive review of toxicity and survival outcomes was performed. Outcomes were stratified by baseline Child‐Pugh (CP) class, United Network for Organ Sharing (UNOS), and Barcelona Clinic Liver Cancer (BCLC) staging systems. Albumin and bilirubin laboratory toxicities were compared to baseline. OS outcomes were reported using censoring and intention‐to‐treat methodologies. All treatments were outpatient, with a median one treatment per patient. Five hundred six (51%) were CP A, 450 (45%) CP B, and 44 (4%) CP C. Two hundred sixty‐three (26%) patients were BCLC A, 152 (15%) B, 541 (54%) C, and 44 (4%) D. Three hundred sixty‐eight (37%) were UNOS T1/T2, 169 (17%) T3, 147 (15%) T4a, 223 (22%) T4b, and 93 (9%) N/M. In CP A patients, censored OS for BCLC A was 47.3 (confidence interval [CI], 39.5‐80.3) months, BCLC B 25.0 (CI, 17.3‐30.5) months, and BCLC C 15.0 (CI, 13.8‐17.7) months. In CP B patients, censored OS for BCLC A was 27 (CI, 21‐30.2) months, BCLC B 15.0 (CI, 12.3‐19.0) months, and BCLC C 8.0 (CI, 6.8‐9.5) months. Forty‐nine (5%) and 110 (11%) patients developed grade 3/4 albumin and bilirubin toxicities, respectively.Conclusion:Based on our experience with 1,000 patients over 15 years, we have made a decision to adopt TARE as the first‐line transarterial LRT for patients with HCC. Our decision was informed by prospective data and incrementally reported demonstrating outcomes stratified by BCLC, applied as either neoadjuvant or definitive treatment. (H epatology 2017).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.29691

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 236

Metadata

Authors
Salem, R., Gabr, A., Riaz, A., Mora, R., Ali, R., Abecassis, M., Hickey, R., Kulik, L., Ganger, D., Flamm, S., Atassi, R., Atassi, B., Sato, K., Benson, A. B., Mulcahy, M. F., Abouchaleh, N., Asadi, A. A., Desai, K., Thornburg, B., Vouche, M., Habib, A., Caicedo, J., Miller, F. H., Yaghmai, V., Kallini, J. R., Mouli, S., & Lewandowski, R. J.
Venue
Hepatology
Published
2018-01-29
Volume
68
Issue
4
Pages
1429-1440
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2772445760
Cited by
236
References
2
FWCI
11.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience. https://app.cochat.ai/papers/10.1002/hep.29691
The paper
Salem, R., Gabr, A., Riaz, A., Mora, R., Ali, R., Abecassis, M., Hickey, R., Kulik, L., Ganger, D., Flamm, S., Atassi, R., Atassi, B., Sato, K., Benson, A. B., Mulcahy, M. F., Abouchaleh, N., Asadi, A. A., Desai, K., Thornburg, B., . . . Lewandowski, R. J. (2018). Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience. Hepatology. https://doi.org/10.1002/hep.29691

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.